Form 8-K - Current report:
SEC Accession No. 0001193125-21-240434
Filing Date
2021-08-09
Accepted
2021-08-09 16:07:21
Documents
18
Period of Report
2021-08-09
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d213858d8k.htm   iXBRL 8-K 34702
2 EX-1.1 d213858dex11.htm EX-1.1 137054
3 EX-4.2 d213858dex42.htm EX-4.2 240060
4 EX-5.1 d213858dex51.htm EX-5.1 17302
9 GRAPHIC g213858dsp005.jpg GRAPHIC 3900
10 GRAPHIC g213858g0806091731881.jpg GRAPHIC 1843
  Complete submission text file 0001193125-21-240434.txt   690712

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA amgn-20210809.xsd EX-101.SCH 4370
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE amgn-20210809_def.xml EX-101.DEF 13774
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE amgn-20210809_lab.xml EX-101.LAB 22822
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE amgn-20210809_pre.xml EX-101.PRE 14743
11 EXTRACTED XBRL INSTANCE DOCUMENT d213858d8k_htm.xml XML 6355
Mailing Address ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320
Business Address ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 (805)447-1000
AMGEN INC (Filer) CIK: 0000318154 (see all company filings)

EIN.: 953540776 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37702 | Film No.: 211156490
SIC: 2836 Biological Products, (No Diagnostic Substances)